Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
Large Venture Financings in November Point to Shift Among Investors
Concern Grows About Realizing Value Rather Than Exits, Burrill & Company Says

SAN FRANCISCO, CA -- (Marketwire) -- 12/03/12 -- At a time when life sciences companies are feeling little leverage in M&A, partnering, and IPO negotiations, a series of large venture rounds completed in November suggests venture investors are willing to pony up additional financing for promising companies in late-stage development to realize the full value of their investments, according to Burrill & Company.

"Capital is expensive today, and life sciences companies too often have little option when negotiating deals," says G. Steven Burrill, CEO of Burrill & Company, a global financial services firm focused on the life sciences. "The recent string of large, late-stage rounds suggests a possible shift in posture among life sciences companies and their investors as there is growing unwillingness to leave substantial value on the table."

Intarcia Therapeutics $210 million financing represented the largest private financing of the month through a combination of existing and new investors. It was among the largest amounts raised by a private biotechnology company in the last 25 years. Intarcia raised $160 million in equity through a preferred stock private placement and $50 million in a private debt placement. Intarcia's ITCA 650 is a once-yearly, injection-free treatment for type 2 diabetes that provides subcutaneous delivery of the already-approved drug exenatide.

TauRx Pharmaceuticals, which had encouraging mid-stage trial results for its experimental Alzheimer's drug, raised $112 million in November. TauRx received $31.5 million as the first tranche of a $111.8 million investment from Genting Management, a unit of the Malaysian conglomerate Genting Berhad, in exchange for a 20 percent stake in the biotech company. TauRx's experimental Alzheimer's drug LMTX, works by keeping the tau proteins from clumping together, and is the first such drug to be tested in a late-stage trial, according to the company.

And then there's Rib-X Pharmaceuticals, which closed an $18.7 million first tranche of a $67.5 million preferred stock financing. A second tranche is expected to close before the end of 2012. New investor Vatera Healthcare Partners joined existing investors in the deal. The money will be used to initiate a late-stage trial of Rib-X's delafloxacin, a treatment for acute bacterial skin and skin structure infections being developed as a first-line therapy for use in hospitals prior to the availability of a specific diagnosis. Unlike available first-line antibiotics, Rib-X says delafloxacin is a broad spectrum antibiotic that has the potential to treat Gram-negative and Gram-positive bacterial infections, including for methicillin-resistant Staphylococcus aureus.

"In the case of these three companies, they are targeting substantial markets with innovative therapies," says Burrill. "These financings may signal that venture investors are growing more confident about the economy, their ability to raise money, and exit investments on their own terms when the time is right."

Overall, life sciences companies raised more than $1.2 billion in venture financings in November, up from $940 million for the same period a year ago. In the United States, life sciences venture financings grew to $928 million in November, up from $700 million a year ago. Through the first 11 months of 2012, both global and U.S. life sciences venture funding are up nearly 23 percent.

In public markets, life sciences stocks rebounded in November after a down month in October. The Burrill Select Index rose 6.6 percent in November, beating the major market indices. For the month, the Dow Jones Industrial Average lost .7 percent, the S&P 500 gained .1 percent and the Nasdaq Composite Index climbed 1 percent.




BURRILL
 INDICES
                                                         Week   Month  Year
Index       12/30/2011 10/31/2012 11/23/2012 11/30/2012 Change Change Change
Burrill
 Select         432.49     575.48     610.17     613.46   0.5%   6.6%  41.8%
Burrill
 Large Cap      529.22     693.83     740.39     740.73   0.0%   6.8%  40.0%
Burrill
 Mid-Cap        295.33     308.82     310.30     311.35   0.3%   0.8%   5.4%
Burrill
 Small Cap       82.75     102.50      99.23     101.78   2.6%  -0.7%  23.0%
Burrill
 Diagnostics    175.42     188.74     189.44     189.79   0.2%   0.6%   8.2%
Burrill
 Personalized
 Medicine       100.62     115.99     117.64     118.40   0.6%   2.1%  17.7%
Burrill
 Biogreentech   149.36     159.77     157.71     161.77   2.6%   1.3%   8.3%
Canadian
 Biotech         59.17      59.98      60.19      60.20   0.0%   0.4%   1.7%
NASDAQ         2605.15    2977.23    2966.85    3005.66   1.3%   1.0%  15.4%
DJIA          12217.56   13096.46   13009.68   13010.61   0.0%  -0.7%   6.5%
S&P 500        1257.60    1412.16    1409.15    1414.13   0.4%   0.1%  12.4%
Amex
 Biotech       1091.42    1397.78    1533.01    1546.52   0.9%  10.6%  41.7%
Amex
 Pharmaceut
 ical           332.94     369.01     364.91     368.27   0.9%  -0.2%  10.6%



Atossa Genetics was the sole life sciences IPO in November. The diagnostics maker, focused on risk assessment for breast cancer, raised $4 million at $4 per share, the bottom of its target range. A total of 16 life sciences companies have completed initial public offerings in the United States through the end of November, the same as last year. Overall, U.S. life sciences IPOs completed in 2012 are up an average of 12 percent from their offering price as of the end of November.

On the M&A front, Reckitt Benckiser said it would acquire the nutraceuticals company Schiff Nutritional International for $1.4 billion in the largest announced deal for the month. Overall, it was a quiet month for M&A transactions as a total of $6.4 billion in deals were announced, down from $14.3 billion in November 2011. Through the end of November $101.1 billion in deals were announced, down 34.5 percent from the activity a year ago.

Total global public financings in November rose to $16.1 billion, an 18.3 percent increase from activity a year ago. But a $14.7 billion debt issue by Abbott Laboratories represented the bulk of the activity in what was an otherwise slow month for public financings of life sciences companies.





Life Sciences Scorecard in USD M
                                     YTD 11/30/12   YTD 11/30/12    Change
Global Venture Capital                      11,240          9,139      23.0%
U.S. VC                                      8,475          6,930      22.3%

IPOs (34 in 2012 v. 44 in 2011)              2,080          3,894     -46.6%
U.S. IPOs (16 in 2012 v. 16 in
 2011)                                       1,093          1,394     -21.6%

Global PIPEs                                 4,978          2,923      70.3%
U.S. PIPEs                                   1,728          1,251      38.1%

Global Follow-ons                            6,565          8,424     -22.1%
U.S. Follow-ons                              5,734          4,618      24.2%

Global Other Equity                          1,858            989      87.9%
U.S. Other Equity                              929            675      37.6%

Global Debt Offerings                       46,616         50,324      -7.4%
U.S. Debt                                   38,024         30,718      23.8%

Global Other Debt                           13,209          9,909      33.3%
U.S. Other Debt                             11,710          4,259     174.9%

Total Global Public Financings              75,306         76,463      -1.5%
Total U.S. Public Financings                59,218         42,915      38.0%

Global Partnering                           34,411         32,662       5.4%
U.S. Partner/Licenser                       18,200         18,984      -4.1%

Global M&A                                 101,124        154,309     -34.5%
M&A, U.S. Target                            72,896         91,861     -20.6%



November marked the first approved product for Exelixis. The FDA gave a green light to Cometriq for the treatment of progressive, metastatic medullary thyroid cancer. The drug inhibits multiple tyrosine kinases involved in the spread of cancer, the growth of tumors and the sustainability of tumors. The approval, which was widely expected, came after close of trading November 29. Exelixis shares closed down 6.9 percent the following day to close at $4.88. The agency also approved Pfizer's Xeljanz for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate. As of the end of November, the FDA approved a total of 31 new drugs and biologics, one more than it approved for the same period a year ago.

Sanofi cut the price of its new cancer drug Zaltrap by half, according to a report in The Cancer Letter. That came in response to a public controversy over the pricing of Zaltrap that erupted after physicians at Memorial Sloan-Kettering Cancer Center authored an op-ed in The New York Times praising their hospital's decision to exclude it from their formulary because of its price and the belief that Avastin, a competing drug, offered the same benefit at half the price. The development is seen as a sign of the growing pressure on drugmakers to prove the value of their new products to justify pricing.

With the re-election of President Barack Obama in November and Democrats retaining a majority in the Senate, the attention in Washington is shifting from efforts to repeal the administration's landmark healthcare reform legislation to matters relating to its implementation. More immediately, though, the focus is on the fiscal cliff and the specter of automatic spending cuts that loom over agencies ranging from the National Institutes of Health to the FDA, and threatens the health of the life sciences industry.

"This industry has much at stake in the debate underway right now," says Burrill. "It is critical that Congress take action and not jeopardize the nation's ability to innovate, create jobs, and compete globally."

About Burrill & Company

Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: www.burrillandco.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Daniel Levine
Managing Director
Burrill & Company
Email Contact
(415) 591-5449

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

SOA World Latest Stories
ScriptRock makes GuardRail, a DevOps-ready platform for configuration monitoring. Realizing we were spending way too much time digging up, cataloguing, and tracking machine configurations, we began writing our own scripts and tools to handle what is normally an enormous chore. Then...
Verizon Enterprise Solutions is simplifying the cloud-purchasing experience for its clients, with the launch of Verizon Cloud Marketplace, a key foundational component of the company's robust ecosystem of enterprise-class technologies. The online storefront will initially feature pre-b...
The BPM world is going through some evolution or changes where traditional business process management solutions really have nowhere to go in terms of development of the road map. In this demo at 15th Cloud Expo, Kyle Hansen, Director of Professional Services at AgilePoint, shows Agile...
SYS-CON Events announced today Isomorphic Software, the global leader in high-end, web-based business applications, will exhibit at SYS-CON's DevOps Summit 2015 New York, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Isomorphic Software is the gl...
"People are a lot more knowledgeable about APIs now. There are two types of people who work with APIs - IT people who want to use APIs for something internal and the product managers who want to do something outside APIs for people to connect to them," explained Roberto Medrano, Execut...
“We are a managed services company. We have taken the key aspects of the cloud and the purposed data center and merged the two together and launched the Purposed Cloud about 18–24 months ago," explained Chetan Patwardhan, CEO of Stratogent, in this SYS-CON.tv interview at 15th Cloud Ex...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE